1. Home
  2. FGI vs MBIO Comparison

FGI vs MBIO Comparison

Compare FGI & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

N/A

Current Price

$7.79

Market Cap

16.0M

Sector

Industrials

ML Signal

N/A

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.52

Market Cap

4.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FGI
MBIO
Founded
1987
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0M
4.1M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
FGI
MBIO
Price
$7.79
$0.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 43.6K
24.1K
Earning Date
04-09-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 98.99
EPS
★ 0.17
N/A
Revenue
N/A
N/A
Revenue This Year
$6.38
N/A
Revenue Next Year
$6.06
N/A
P/E Ratio
$45.06
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.14
$0.47
52 Week High
$19.93
$1.84

Technical Indicators

Market Signals
Indicator
FGI
MBIO
Relative Strength Index (RSI) 47.66 44.30
Support Level $6.63 $0.47
Resistance Level $10.30 $0.56
Average True Range (ATR) 0.80 0.03
MACD -0.21 0.00
Stochastic Oscillator 14.24 58.80

Price Performance

Historical Comparison
FGI
MBIO

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, it generates the majority of its revenue from the United States, followed by Canada and Europe.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: